Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001

Kevin C Katz; Allison J McGeer; Carla L Duncan; Aisha Ashi-Sulaiman; Barbara M Willey; Alicia Sarabia; Jacquie McCann; Sylvia Pong-Porter; Yana Rzayev; Joyce S de Azavedo; Donald E Low

doi:10.1128/AAC.47.7.2370-2372.2003

Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001

Antimicrob Agents Chemother. 2003 Jul;47(7):2370-2. doi: 10.1128/AAC.47.7.2370-2372.2003.

Authors

Kevin C Katz¹, Allison J McGeer, Carla L Duncan, Aisha Ashi-Sulaiman, Barbara M Willey, Alicia Sarabia, Jacquie McCann, Sylvia Pong-Porter, Yana Rzayev, Joyce S de Azavedo, Donald E Low

Affiliation

¹ Toronto Medical Laboratories/Mount Sinai Hospital Department of Microbiology. University of Toronto, Toronto, Ontario, Canada.

Abstract

Of 500 group A streptococci isolated from pharyngeal swabs, 72 (14.4%) were macrolide resistant, compared to 2.1% in 1997. Of these, 66 (92%) were of the M phenotype and 6 (8.3%) were of the MLS phenotype. Pulsed-field gel electrophoresis found that two clones, with patterns identical to those of serotypes M1 and M4, accounted for 19.4 and 68.1% of the macrolide-resistant isolates, respectively.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Clindamycin / pharmacology
Drug Resistance, Bacterial
Erythromycin / pharmacology*
Humans
Ketolides*
Macrolides*
Microbial Sensitivity Tests
Ontario / epidemiology
Pharynx / microbiology
Prevalence
Streptococcal Infections / drug therapy*
Streptococcal Infections / epidemiology
Streptococcus pyogenes / drug effects*

Substances

Anti-Bacterial Agents
Ketolides
Macrolides
Clindamycin
Erythromycin
telithromycin